A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.

An increasing number of broadly neutralizing monoclonal antibodies (bnMAb) against the HIV-1 envelope (Env) protein has been discovered recently. Despite this progress, vaccination efforts with the aim to re-elicit bnMAbs that provide protective immunity have failed so far. Herein, we describe the d...

Full description

Bibliographic Details
Main Authors: Tim-Henrik Bruun, Katharina Mühlbauer, Thomas Benen, Alexander Kliche, Ralf Wagner
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4184847?pdf=render
_version_ 1818997757435707392
author Tim-Henrik Bruun
Katharina Mühlbauer
Thomas Benen
Alexander Kliche
Ralf Wagner
author_facet Tim-Henrik Bruun
Katharina Mühlbauer
Thomas Benen
Alexander Kliche
Ralf Wagner
author_sort Tim-Henrik Bruun
collection DOAJ
description An increasing number of broadly neutralizing monoclonal antibodies (bnMAb) against the HIV-1 envelope (Env) protein has been discovered recently. Despite this progress, vaccination efforts with the aim to re-elicit bnMAbs that provide protective immunity have failed so far. Herein, we describe the development of a mammalian cell based FACS-panning method in which bnMAbs are used as tools to select surface-exposed envelope variants according to their binding affinity. For that purpose, an HIV-1 derived lentiviral vector was developed to infect HEK293T cells at low multiplicity of infection (MOI) in order to link Env phenotype and genotype. For proof of principle, a gp145 Env model-library was established in which the complete V3 domain was substituted by five strain specific V3 loop sequences with known binding affinities to nMAb 447-52D, respectively. Env genes were recovered from selected cells by PCR, subcloned into a lentiviral vector (i) to determine and quantify the enrichment nMAb binders and (ii) to generate a new batch of transduction competent particles. After 2 selection cycles the Env variant with highest affinity was enriched 20-fold and represented 80% of the remaining Env population. Exploiting the recently described bnMAbs, this procedure might prove useful in selecting Env proteins from large Env libraries with the potential to elicit bnMAbs when used as vaccine candidates.
first_indexed 2024-12-20T21:50:42Z
format Article
id doaj.art-170e65fbca1d494abc44399898f08499
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-20T21:50:42Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-170e65fbca1d494abc44399898f084992022-12-21T19:25:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e10919610.1371/journal.pone.0109196A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.Tim-Henrik BruunKatharina MühlbauerThomas BenenAlexander KlicheRalf WagnerAn increasing number of broadly neutralizing monoclonal antibodies (bnMAb) against the HIV-1 envelope (Env) protein has been discovered recently. Despite this progress, vaccination efforts with the aim to re-elicit bnMAbs that provide protective immunity have failed so far. Herein, we describe the development of a mammalian cell based FACS-panning method in which bnMAbs are used as tools to select surface-exposed envelope variants according to their binding affinity. For that purpose, an HIV-1 derived lentiviral vector was developed to infect HEK293T cells at low multiplicity of infection (MOI) in order to link Env phenotype and genotype. For proof of principle, a gp145 Env model-library was established in which the complete V3 domain was substituted by five strain specific V3 loop sequences with known binding affinities to nMAb 447-52D, respectively. Env genes were recovered from selected cells by PCR, subcloned into a lentiviral vector (i) to determine and quantify the enrichment nMAb binders and (ii) to generate a new batch of transduction competent particles. After 2 selection cycles the Env variant with highest affinity was enriched 20-fold and represented 80% of the remaining Env population. Exploiting the recently described bnMAbs, this procedure might prove useful in selecting Env proteins from large Env libraries with the potential to elicit bnMAbs when used as vaccine candidates.http://europepmc.org/articles/PMC4184847?pdf=render
spellingShingle Tim-Henrik Bruun
Katharina Mühlbauer
Thomas Benen
Alexander Kliche
Ralf Wagner
A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.
PLoS ONE
title A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.
title_full A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.
title_fullStr A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.
title_full_unstemmed A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.
title_short A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.
title_sort mammalian cell based facs panning platform for the selection of hiv 1 envelopes for vaccine development
url http://europepmc.org/articles/PMC4184847?pdf=render
work_keys_str_mv AT timhenrikbruun amammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT katharinamuhlbauer amammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT thomasbenen amammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT alexanderkliche amammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT ralfwagner amammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT timhenrikbruun mammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT katharinamuhlbauer mammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT thomasbenen mammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT alexanderkliche mammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment
AT ralfwagner mammaliancellbasedfacspanningplatformfortheselectionofhiv1envelopesforvaccinedevelopment